{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-024906","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2026-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.632108+00:00","generated_at":"2026-05-15T06:35:29.622853+00:00","sec_items":["2.02","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Spyre reports preliminary $741M cash; suspends ATM offering","bullets":["Preliminary cash, equivalents and marketable securities of $741M as of March 31, 2026.","Includes $30M legacy asset disposition proceeds; $23M expected to be paid to CVR holders in Q2 2026.","Effective April 13, 2026, terminated ATM prospectus; no further share sales under Sales Agreement until new filing.","Sales Agreement with TD Securities remains in force; company funded without current need for dilution."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-024906","json":"https://secwatch.observer/filing/0001628280-26-024906.json","markdown":"https://secwatch.observer/filing/0001628280-26-024906.md","text":"https://secwatch.observer/filing/0001628280-26-024906.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000162828026024906/0001628280-26-024906-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000162828026024906/syre-20260413.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:35:29.622853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"75b5b8d23c8dd3ad0dd09aa34b58c89dd242cddb","claim":"Spyre Therapeutics, Inc. reported preliminary financial results for the quarter ended March 31, 2026.","evidence_excerpt":"the Company expects to report that it had approximately $741 million of cash, cash equivalents and marketable securities as of March 31, 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000162828026024906/0001628280-26-024906-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001193125-26-215803","ticker":"LMFA","company_name":"LM FUNDING AMERICA, INC.","filed_at":"2026-05-11T23:59:59+00:00","headline":"LM Funding April Bitcoin production flat at 9.4 BTC; HODL slips to 334.0","event_type":"other_material","sec_items":["2.02","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-215803","json":"https://secwatch.observer/filing/0001193125-26-215803.json","markdown":"https://secwatch.observer/filing/0001193125-26-215803.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640384/000119312526215803/0001193125-26-215803-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640384/000119312526215803/lmfa-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"the Company expects to report that it had approximately $741 million of cash, cash equivalents and marketable securities as of March 31, 2026","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000162828026024906/0001628280-26-024906-index.htm","comparable_excerpt":"LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a Bitcoin treasury and mining company, today announced its preliminary, unaudited Bitcoin mining and operational update for the month ended April 30, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1640384/000119312526215803/0001193125-26-215803-index.htm"}},{"accession":"0001193125-26-213239","ticker":"ARTV","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Artiva reports 71% ACR50 in refractory RA at 6 months, FDA alignment for Phase 3 trial; Q1 net loss $23.5M","event_type":"other_material","sec_items":["2.02","7.01","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 8.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-213239","json":"https://secwatch.observer/filing/0001193125-26-213239.json","markdown":"https://secwatch.observer/filing/0001193125-26-213239.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/0001193125-26-213239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/d38160d8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"the Company expects to report that it had approximately $741 million of cash, cash equivalents and marketable securities as of March 31, 2026","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000162828026024906/0001628280-26-024906-index.htm","comparable_excerpt":"Artiva Biotherapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the quarter ended March 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/0001193125-26-213239-index.htm"}},{"accession":"0001315257-26-000036","ticker":"KOP","company_name":"Koppers Holdings Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Koppers conditionally plans to shut Stickney, IL chemical operations; Q1 adjusted EPS down 19.7%","event_type":"other_material","sec_items":["2.02","2.05","5.02","5.07","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001315257-26-000036","json":"https://secwatch.observer/filing/0001315257-26-000036.json","markdown":"https://secwatch.observer/filing/0001315257-26-000036.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1315257/000131525726000036/0001315257-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1315257/000131525726000036/kop-20260507.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"the Company expects to report that it had approximately $741 million of cash, cash equivalents and marketable securities as of March 31, 2026","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000162828026024906/0001628280-26-024906-index.htm","comparable_excerpt":"McGuireQT@koppers.com Koppers Holdings Inc. 436 Seventh Avenue Pittsburgh, PA 15219-1800 Tel 412 227 2001 www.koppers.com KOPPERS REPORTS FIRST QUARTER 2026 RESULTS • Sales of $455.3 million vs. $456.5 million in Prior Year Quarter • Net income (loss) of $7.1 million vs. $(13.9) million in Prior Year Quarter • Diluted EPS of $0.35 vs. $(0.68) in Prior Year Quarter •","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1315257/000131525726000036/0001315257-26-000036-index.htm"}},{"accession":"0001043000-26-000016","ticker":"SNDA","company_name":"SONIDA SENIOR LIVING, INC.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Sonida Senior Living reports Q1 net loss of $41.2M; revenue up 37% on CHP acquisition","event_type":"earnings","sec_items":["2.02","8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 8.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001043000-26-000016","json":"https://secwatch.observer/filing/0001043000-26-000016.json","markdown":"https://secwatch.observer/filing/0001043000-26-000016.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1043000/000104300026000016/0001043000-26-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1043000/000104300026000016/snda-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"the Company expects to report that it had approximately $741 million of cash, cash equivalents and marketable securities as of March 31, 2026","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000162828026024906/0001628280-26-024906-index.htm","comparable_excerpt":"Sonida Senior Living Announces First Quarter 2026 Results DALLAS, Texas – May 11, 2026 – Sonida Senior Living, Inc. (the “Company,” “Sonida,” “we,” “our,” or “us”) (NYSE: SNDA), a leading owner, operator and investor of senior housing communities, today announced its results for the first quarter ended March 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1043000/000104300026000016/0001043000-26-000016-index.htm"}},{"accession":"0001193125-26-215674","ticker":"LXEO","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Lexeo Therapeutics Q1 net loss $20.2M; cash $227.6M; LX2006 pivotal trial protocol submitted to FDA","event_type":"earnings","sec_items":["2.02","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 8.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-215674","json":"https://secwatch.observer/filing/0001193125-26-215674.json","markdown":"https://secwatch.observer/filing/0001193125-26-215674.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000119312526215674/0001193125-26-215674-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000119312526215674/lxeo-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"the Company expects to report that it had approximately $741 million of cash, cash equivalents and marketable securities as of March 31, 2026","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000162828026024906/0001628280-26-024906-index.htm","comparable_excerpt":"Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1907108/000119312526215674/0001193125-26-215674-index.htm"}},{"accession":"0001656472-26-000032","ticker":"CRON","company_name":"Cronos Group Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Cronos Q1 net revenue up 40% to $45.2M; authorizes $50M share buyback; CanAdelaar close extended to Sep 9","event_type":"earnings","sec_items":["1.01","2.02","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 8.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001656472-26-000032","json":"https://secwatch.observer/filing/0001656472-26-000032.json","markdown":"https://secwatch.observer/filing/0001656472-26-000032.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1656472/000165647226000032/0001656472-26-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1656472/000165647226000032/cron-20260508.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"the Company expects to report that it had approximately $741 million of cash, cash equivalents and marketable securities as of March 31, 2026","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000162828026024906/0001628280-26-024906-index.htm","comparable_excerpt":"reference in such a filing or document. \n\n--- EX-99.1 (EX-99.1) ---\n\nCronos Group Reports 2026 First Quarter Results Net revenue in Q1 2026 increased by 40% year-over-year to $45.2 million Achieved record net revenue and gross profit in Q1 2026 Reached #1 market share in vapes in Canada 1 Ninth consecutive quarter of record net revenue in Israel, where PEACE","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1656472/000165647226000032/0001656472-26-000032-index.htm"}},{"accession":"0001827090-26-000017","ticker":"CERT","company_name":"Certara, Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Certara Q1 revenue $106.9M (+1%), net loss $8.8M; divests Regulatory Writing for $85M cash","event_type":"earnings","sec_items":["2.02","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 8.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001827090-26-000017","json":"https://secwatch.observer/filing/0001827090-26-000017.json","markdown":"https://secwatch.observer/filing/0001827090-26-000017.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1827090/000182709026000017/0001827090-26-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1827090/000182709026000017/certara-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"the Company expects to report that it had approximately $741 million of cash, cash equivalents and marketable securities as of March 31, 2026","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000162828026024906/0001628280-26-024906-index.htm","comparable_excerpt":"First Quarter 2026 Results Total revenue for the first quarter of 2026 was $106.9 million, representing year-over-year growth of 1% on a reported basis. Software revenue for the first quarter of 2026 was $49.7 million, representing year-over-year growth of 7% on a reported basis. Services revenue for the first quarter of 2026 was $57.2 million, representing a year-over-year decrease of 4% on a reported basis . Total Bookings for the first quarter of 2026 were $115.3 million, representing a year-over-year decrease of 2%. Software Bookings for the first quarter of 2026 were $48.7 million, representing a year-over-year increase of 20%. The increase in software bookings was attributable to strong customer demand across our platform. Services Bookings for the first quarter of 2026 were $66.6 million, representing a year-over-year decrease of 14%. The decrease in services bookings was primarily driven by the timing of contract recognition and execution. Total cost of revenues for the first q","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1827090/000182709026000017/0001827090-26-000017-index.htm"}},{"accession":"0001193125-26-213371","ticker":"RPC","company_name":"Ridgepost Capital, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Ridgepost Capital reports record AUM of $31B in Q1 2026, up 18% YoY","event_type":"earnings","sec_items":["2.02","7.01","8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 8.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-213371","json":"https://secwatch.observer/filing/0001193125-26-213371.json","markdown":"https://secwatch.observer/filing/0001193125-26-213371.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841968/000119312526213371/0001193125-26-213371-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841968/000119312526213371/rpc-20260507.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"the Company expects to report that it had approximately $741 million of cash, cash equivalents and marketable securities as of March 31, 2026","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000162828026024906/0001628280-26-024906-index.htm","comparable_excerpt":"Ridgepost Capital, Inc (NYSE: RPC), a leading private markets solutions provider, today announced financial results for the first quarter ended March 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1841968/000119312526213371/0001193125-26-213371-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}